/PRNewswire/ Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today.
May 17, 2021 11:35am The Navitor artificial heart valve is implanted using Abbott’s CE-marked FlexNav delivery device and reduces the blood leaks that often occur after replacement. (Abbott)
After Boston Scientific retired its entire line of Lotus Edge replacement heart valves late last year amid a flurry of issues with its delivery system, Abbott has stepped up to fill in the gap in the transcatheter aortic valve replacement market.
Abbott’s Navitor TAVR system has received a CE mark, making it available in Europe to those with severe aortic stenosis and a high or extreme risk of complications from surgery.
TAVR systems offer a less risky, minimally invasive alternative to open-heart surgery to treat aortic stenosis, where the aortic valve narrows and restricts blood flow out of the left ventricle to the aorta, weakening the heart muscle over time as it s forced to work harder.
Amunix Pharmaceuticals raises $117 million to pivot to cancer drugs - San Francisco Business Times bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.